Mirum Pharmaceuticals, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Mirum Pharmaceuticals, Inc. (MIRM) had Deferred Tax Assets, Operating Loss Carryforwards of $45.30 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-02-25
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $45.30M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $38.40M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $40.45M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $34.52M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $45.30M 10-K · filed 2026-02-25 |
| 2024-12-31 | $38.40M 10-K · filed 2026-02-25 |
| 2023-12-31 | $40.45M 10-K · filed 2025-02-26 |
| 2022-12-31 | $34.52M 10-K · filed 2024-03-15 |
| 2021-12-31 | $31.82M 10-K · filed 2023-03-08 |
| 2020-12-31 | $26.12M 10-K · filed 2022-03-09 |
| 2019-12-31 | $9.49M 10-K · filed 2021-03-09 |
| 2018-12-31 | $602.00K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |